Details for Patent: 7,500,444
✉ Email this page to a colleague
Which drugs does patent 7,500,444 protect, and when does it expire?
Patent 7,500,444 protects FLOVENT HFA and is included in one NDA.
Protection for FLOVENT HFA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-nine patent family members in seventeen countries.
Summary for Patent: 7,500,444
| Title: | Actuation indicator for a dispensing device |
| Abstract: | An actuation indicator that includes a drum sub-assembly, which includes a rotatable actuation indicator wheel, a rocking, ratchet pawl for rotating the indicator wheel in a set direction and a rocking mechanism for the pawl driven by a slipping clutch arrangement, is described. The slipping clutch arrangement includes a slipping clutch spring engaged at one end to a pinion of a rack and pinion assembly and at a second end to the ratchet pawl. |
| Inventor(s): | Bonney; Stanley George (Ware, GB), Brand; Peter John (Ware, GB), Godfrey; James William (Ware, GB), Rand; Paul Kenneth (Ware, GB) |
| Assignee: | Glaxo Group Limited (Greenford, Middlesex, GB) |
| Application Number: | 10/518,421 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,500,444 |
|
Patent Claim Types: see list of patent claims | Use; |
Recent additions to Drugs Protected by US Patent 7,500,444
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 7,500,444
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-002 | May 14, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,500,444
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0214360.0 | Jun 21, 2002 |
| United Kingdom | 0311191.1 | May 15, 2003 |
| PCT Information | |||
| PCT Filed | June 19, 2003 | PCT Application Number: | PCT/EP03/06466 |
| PCT Publication Date: | December 31, 2003 | PCT Publication Number: | WO04/001664 |
International Family Members for US Patent 7,500,444
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 424010 | ⤷ Sign Up | |||
| Australia | 2003278236 | ⤷ Sign Up | |||
| Brazil | 0311557 | ⤷ Sign Up | |||
| Brazil | PI0311557 | ⤷ Sign Up | |||
| Canada | 2489554 | ⤷ Sign Up | |||
| China | 101853424 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
